VIDEX EC Drug Patent Profile
✉ Email this page to a colleague
When do Videx Ec patents expire, and when can generic versions of Videx Ec launch?
Videx Ec is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in VIDEX EC is didanosine. There are eight drug master file entries for this compound. Additional details are available on the didanosine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIDEX EC?
- What are the global sales for VIDEX EC?
- What is Average Wholesale Price for VIDEX EC?
Summary for VIDEX EC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 124 |
| Patent Applications: | 5,251 |
| Drug Prices: | Drug price information for VIDEX EC |
| What excipients (inactive ingredients) are in VIDEX EC? | VIDEX EC excipients list |
| DailyMed Link: | VIDEX EC at DailyMed |
Paragraph IV (Patent) Challenges for VIDEX EC
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VIDEX EC | Delayed-release Capsules | didanosine | 200 mg, 250 mg and 400 mg | 021183 | 1 | 2004-06-01 |
US Patents and Regulatory Information for VIDEX EC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-001 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-004 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-002 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-003 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIDEX EC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-002 | Oct 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-004 | Oct 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-001 | Oct 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-003 | Oct 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-004 | Oct 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIDEX EC
See the table below for patents covering VIDEX EC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 9014091 | ⤷ Sign Up | |
| Austria | 96325 | ⤷ Sign Up | |
| Netherlands | 940005 | ⤷ Sign Up | |
| Japan | S62501712 | ⤷ Sign Up | |
| New Zealand | 217185 | ALLEVIATING CYTOPATHIC EFFECTS OF HTLV-III VIRUS ON CELLS; PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIDEX EC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0216510 | SPC/GB94/005 | United Kingdom | ⤷ Sign Up | SPC/GB94/005:, EXPIRES: 20070504 |
| 0216510 | SZ 54/1994 | Austria | ⤷ Sign Up | PRODUCT NAME: 2',3'-DIDEOXYINOSIN |
| 0285237 | 94C0006 | France | ⤷ Sign Up | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| 0216510 | 94C0006 | Belgium | ⤷ Sign Up | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
